NICE TAs
- 05/03/2020
- TA367: Vortioxetine for treating major depressive episodes
-
-
-
Published date: We reviewed the evidence in November 2018. We found nothing new that affects the recommendations in this guidance.
- 05/03/2020
- TA272: Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
-
-
-
Published date: We reviewed the evidence in January 2016. We found nothing new that affects the recommendations in this guidance.
- 05/03/2020
- TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
-
-
-
Published date: We reviewed the evidence in July 2017. We found nothing new that affects the recommendations in this guidance.
- 05/03/2020
- TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
-
-
-
Published date: We reviewed the evidence in March 2018. We found nothing new that affects the recommendations in this guidance.
- 05/03/2020
- TA482: Immunosuppressive therapy for kidney transplant in children and young people
-
-
-
Published date: Next review: 2020
- 05/03/2020
- TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
-
-
-
Published date: In July 2017, we decided that we will review the evidence within 6 months of publication of the PIX306 trial results.
- 05/03/2020
- TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
-
-
-
Published date: Next review: 2019
- 05/03/2020
- TA610: Pentosan polysulfate sodium for treating bladder pain syndrome
-
-
-
Published date: Next review: 2022
There is a simple discount patient access scheme for pentosan polysulfate sodium
- 05/03/2020
- TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
-
-
-
Published date: Next review: 2019 This guidance replaces TA309.
- 05/03/2020
- TA339: Omalizumab for previously treated chronic spontaneous urticaria
-
-
-
Published date:
We reviewed the evidence in July 2018. We found nothing new that affects the recommendations in this guidance.
- 05/03/2020
- TA494: Naltrexone–bupropion for managing overweight and obesity
-
-
-
Published date: We reviewed the evidence in January 2020. We found nothing new that affects the recommendations in this guidance.
- 05/03/2020
- TA318: Lubiprostone for treating chronic idiopathic constipation
-
-
-
This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza).
- 05/03/2020
- TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
-
-
-
Published date: Next review: 2021
- 05/03/2020
- TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
-
-
-
Published date: Next review: 2021
- 05/03/2020
- TA359: Idelalisib for treating chronic lymphocytic leukaemia
-
-
-
Published date: We reviewed the evidence in September 2018. We found nothing new that affects the recommendations in this guidance.
September 2016: The European Medicines Agency has reviewed idelalisib and the marketing authorisation has been updated.
For people taking idelalisib as a first therapy, the marketing authorisation now states that idelalisib is for ‘first-line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies’.
Additional information about infections has been included in the marketing authorisation.
- 05/03/2020
- TA491: Ibrutinib for treating Waldenstrom's macroglobulinaemia
-
-
-
Published date: Next review: More evidence on ibrutinib is being collected, until September 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
- 05/03/2020
- TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
-
-
-
Published date: Next review: 2020
- 05/03/2020
- TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
-
-
-
Published date: Next review: 2021
- 05/03/2020
- TA481: Immunosuppressive therapy for kidney transplant in adults
-
-
-
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).
Published date: Next review: 2020
- 05/03/2020
- TA348: Everolimus for preventing organ rejection in liver transplantation
-
-
-
Published date: We reviewed the evidence in July 2018. We found nothing new that affects the recommendations in this guidance.